Motus GI Holdings, Inc. · OTC:MOTS
Motus GI — Investor Presentation (March 2018)
26 slides from Motus GI's investor presentation, Mar 20, 2018
Slide 1: Developing Breakthrough Solutions for Endoscopy
Developing Breakthrough Solutions for Endoscopy MARCH 2018
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘This presentation contains certain forward-looking statements, including those relating to the Company's product development. linical studies, clinical and regulatory timelines, market ‘opportunity, competitive position, possible or assumed future results of operations, b
Slide 3: Overview
OVERVIEW luct for colonoscopy ~ Pure-Vu® opy procedures worldwide annually i Driving clinical data collection to maximize market value Benefiting patients, physicians and payers Mul product ex} h prover
Slide 4: Potential to Address Significant Unmet Clinical Needs
POTENTIAL TO ADDRESS SIGNIFICANT UNMET CLINICAL NEEDS Targeting Average Selling Price (ASP) of $250 Per Procedure Disposable Kit Initial Pure-Vu® Market Broad Market Launch Opportunity Clinical Data Drives a Market Penetration re and| Growth. wonanieeonescopy pportunity disease 10) | anemia ower | s
Slide 5: Pure-Vu
PURE-VU y moTUS™ PLAY VIDEO > mts
Slide 6: Pure-Vu Overview
PURE-VU® OVERVIEW.
Slide 7: Problems with Conventional Colonoscopy Prep
PROBLEMS WITH CONVENTIONAL COLONOSCOPY PREP 57% of Patients Cite Fear of Bowel Prep as “1 Deterrent of Procedure’ 50098 Clear Liquid Diet Potent Prep - 4L Repeated Visits Missed Work —_papteduced Complications Awful taste and Cramping/ Work disrupted High fare rate in ~23%6 with fasting Targe volume
Slide 8: Pure-Vu Improves Colonoscopy Experience
PURE-VU® IMPROVES COLONOSCOPY EXPERIENCE Micro-Prep Able to Eat OTC Mild Laxative y ; e a mous NS dibs Low Residue Diet 102. bottie (eggs, toast, pasta, etc.) (magnesium citrate) Company Working to Expand Pure-Vu Indication to Actively Promote Micro-Prep Capabilities
Slide 9: Go-to-Market Strategy: Targeting Large Segments with Clear Value Proposition
GO-TO-MARKET STRATEGY: TARGETING LARGE SEGMENTS WITH CLEAR VALUE PROPOSITION Market Segments Global Opportunity Value: Lower costs, speed diagnosis, DRG-based reimbursement In-Patients: Improving Outcomes and Costs | 4.1m Key populations: Lower GI bleeds; Elderly, Comorbidities, VA patients Procedur
Slide 10: In-Patient Colonoscopy Represents Significant Unmet Need
IN-PATIENT COLONOSCOPY REPRESENTS SIGNIFICANT UNMET NEED Existing DRG-Based Reimbursement Creates Potential for Strong Economic Incentive to Adopt Pure-Vu as Standard of Care Of cases present Longer length of stay* Increase in hospital costs with insufficient * Long procedure times * Averages “$8,00
Slide 11: In-Patients Studies: Improving Outcomes and Costs
IN-PATIENTS STUDIES: IMPROVING OUTCOMES AND COSTS Reliably and Predictably Move Patients Through System to Successful Exam a sce | ss | uses estes — REDUCE Study - multicenter in- F Supports significant cost avoidance patient prospective trial Bees Eres OE as + Drives hospital value analysis committ
Slide 12: Out-Patient: High Medical Need / Difficult to Prep
OUT-PATIENT: HIGH MEDICAL NEED / DIFFICULT TO PREP )| =» “23% Inability to comply with Ability to target Additional Drivers: Of out-patient standard prep leads to patients prior to A fier population present unsuccessful exam*: start of procedure ate cones Nanon with inadequate Predictors: Diabetics,
Slide 13: Out-Patient: Patients Highly Motivated for Better Experience
OUT-PATIENT: PATIENTS HIGHLY MOTIVATED FOR BETTER EXPERIENCE + Patient Out-of-Pocket Pay Creates New High Margin Revenue Source for Physician + Allows the Ability to Preform Cases Later in the Day 83% 58% Willing to pay Would consider Would consider out-of-pocket paying up to $350** paying up to $25
Slide 14: Out-Patients Studies: Driving Quality and Patient Satisfaction
OUT-PATIENTS STUDIES: DRIVING QUALITY AND PATIENT SATISFACTION Supports Reimbursement and Enables Micro-prep DTC Marketing a sce | ss | uses estes — ee ledical Need / Difficu Results Expected Meter Neer | Denos + Supports reimbursement to Prep Populations #22019 me = Results Expected + Guides micro-
Slide 15: Clinical Results Indicate Outstanding Cleaning Performance
CLINICAL RESULTS INDICATE OUTSTANDING CLEANING PERFORMANCE Study Prep: “18 hour full liquid diet and Dulcola» % of Subjects Adequately Prepped Boston Bowel Preparation Scale (BBPS) According to BBPS Standard* Score Before and After Pure-Vu? Multicenter Study 1(N=48) 5.04152 882114 Multicenter Study
Slide 16: Increased Cleanliness Correlates to Reduced Risk of CRC
i INCREASED CLEANLINESS CORRELATES TO REDUCED RISK OF CRC 4 Increase in Increases Leads to Decreased Cleanliness Detection Rate Risk of CRC Pama siete a 13% 030 g _ = § 080 ' gi 2 3 oso jo» 12 2 on | 2 Y= Decrease in CRC Risk Total BPS Score Adenoma Detection Rate(ADR)
Slide 17: Pure-Vu Aligns Physician with Patients and Payers
PURE-VU® ALIGNS PHYSICIAN WITH PATIENTS AND PAYERS Potential for Significant Cost Avoidance for Hospital In- patients Potential Path to Reimbursement for High Medical Need / Difficult to Prep Population K Y ‘Opportunity to Improve Patient Satisfaction and Quality of Exam Payers ; ‘ Prysicans/ Opport
Slide 18: Clear Pathway to Become Standard of Care
CLEAR PATHWAY TO BECOME STANDARD OF CARE Focused on sustainable long-term growth 2018 2020 BEYOND Market Development: today Driving nical / health economic data Developing practice management model ‘Building physician champions Fall market Iaunch Seale manufacturing and logics Reimbursement for colo
Slide 19: Expected Near-Term Value-Driving Milestones
EXPECTED NEAR-TERM VALUE-DRIVING MILESTONES ¥ CE mark approval + Launch slim-scope Publications on in-patient Targeted launch of micro- compatible system studies and micro-pre rep DTP campaign + Initiate post-market sili, pee prep si patient studies * Initiate high medical FDA micro-prep clearance I
Slide 20: Robust Intellectual Property
ROBUST INTELLECTUAL PROPERTY Covers Innovative Portfolio of Technologies Rooted in Systems and Methods for Cleaning Body Cavities With or Without the Use of Endoscope Issued patents in Pending patents Pending patents United States and in United States outside United Europe States
Slide 21: $17.5 Million Initial Public Offering in February 2018
$17.5 Million Initial Public Offering in February 2018 Market Cap: $75M* Common Shares Outstanding: ~15.6M FINANCIAL PROFILE: NASD. MOTS : Average Daily Volume: ~90K* Cash Balance: ~$20M" l
Slide 22: Management Team
“MANAGEMENT TEAM ‘Mark Pomeranz, Chief Executive Officer Andrew L. Taylor, MBA, Chief Financial Hagit Ephrath, VP, Clinical Regulatory Officer ‘and Health Economics 30 years of experience in the medical device (Over 20 years of experience serving 25 2 Neariy 20 years of mesial device experience indu
Slide 23: Board of Directors
F BOARD OF DIRECTORS David Hochman Gary Jacobs hervinKorangy Samuel Nussbaum Chatman Decor of Corts Ader, Managing Director, acobs FO and chet Srategyortcer ot | Former EVE Circa Heath Pty Cie andfactient Managing | Imestnat Company Seovervanecirrtatorat” | &CMO ot nam ines one of Fartne, Orhesta Me
Slide 24: Physician Advisory Board
PHYSICIAN ADVISORY BOARD Gerald Bertiger, MD ‘Managing Partner and President of Hilmont, Gi, PC; Section Chiet of Gastroenterology and Director of, the Endoscopy Unit at Chestrut Hil Hospital Hillmont G1. David Lieberman, MD, FACG Professor of Medicine, hie, Dhision of Gastroenterology and Hepatolog
Slide 25: Revolutionizing the large and growing GI endoscopy market
Revolutionizing the large and growing GI endoscopy market Targeting a multi-billion dollar market opportunity INVESTMENT HIGHLIGHTS Building a strong foundation of clinical and health economic data Pathway to become standard of care Highly-experienced management team with proven track record moTUSs'
Slide 26: Thank you
Thank you INFO@MOTUSGI.COM NASDAQ: MOTS
Motus GI Holdings — Investor Presentation (March 2018) on 6ix